Repare Therapeutics (RPTX)
(Delayed Data from NSDQ)
$3.02 USD
-0.19 (-5.92%)
Updated Apr 18, 2024 04:00 PM ET
After-Market: $3.00 -0.02 (-0.66%) 7:34 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Income Statements
Fiscal Year end for Repare Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 51 | 132 | 8 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 51 | 132 | 8 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 167 | 152 | 116 | 54 | 26 |
Income After Depreciation & Amortization | -116 | -20 | -109 | -54 | -26 |
Non-Operating Income | 13 | 6 | 0 | 0 | -1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -103 | -14 | -109 | -55 | -27 |
Income Taxes | -9 | 15 | -2 | -1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -94 | -29 | -107 | -53 | -27 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -94 | -29 | -107 | -53 | -27 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -122 | -20 | -107 | -53 | -26 |
Depreciation & Amortization (Cash Flow) | -6 | 0 | 2 | 1 | 1 |
Income After Depreciation & Amortization | -116 | -20 | -109 | -54 | -26 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 42.09 | 41.92 | 37.82 | 20.05 | NA |
Diluted EPS Before Non-Recurring Items | -2.23 | -0.69 | -2.83 | -2.66 | NA |
Diluted Net EPS (GAAP) | -2.23 | -0.69 | -2.83 | -2.66 | NA |
Fiscal Year end for Repare Therapeutics Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 13.05 | 2.16 | 30.25 | 5.68 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 13.05 | 2.16 | 30.25 | 5.68 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 43.92 | 40.58 | 42.51 | 40.36 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -30.87 | -38.42 | -12.26 | -34.68 |
Non-Operating Income | NA | 3.03 | 3.24 | 3.42 | 3.36 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -27.84 | -35.18 | -8.84 | -31.33 |
Income Taxes | NA | 0.19 | -16.30 | 3.11 | 3.62 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -28.03 | -18.88 | -11.95 | -34.94 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -28.03 | -18.88 | -11.95 | -34.94 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 42.09 | 42.10 | 42.09 | 42.04 |
Diluted EPS Before Non-Recurring Items | NA | -0.67 | -0.45 | -0.28 | -0.83 |
Diluted Net EPS (GAAP) | NA | -0.67 | -0.45 | -0.28 | -0.83 |